European Regulators Approve Vifor Fresenius’ Velphoro
Europe’s regulatory body, the European Commission, has approved Vifor Fresenius Medical Care Renal Pharma’s hyperphosphatemia drug Velphoro. The regulatory approval for Velphoro, formerly known as PA21, was centered on results from a Phase III clinical trial, which showed that Velphoro successfully controls the accumulation of phosphorus in the blood.